7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients

NCT ID: NCT00841035

Last Updated: 2017-05-19

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-02-28
• Study Completion Date: 2011-07-31

Brief Summary

1.1 Primary Objective

To evaluate the effects of short course preoperative erlotinib treatment in a panel of predictive biomarkers from a group of patients who undergo resection of pancreatic adenocarcinoma with curative intent.

1.2 Secondary Objectives

1.2.1 To analyze the effects of short course preoperative erlotinib treatment followed by postoperative erlotinib-gemcitabine therapy in the disease-free survival of patients who undergo curative intent resection of pancreatic adenocarcinoma.

1.2.2 To evaluate secondary endpoints of disease response such as duration of overall survival and patterns of recurrence for patients with resectable pancreatic cancer who undergo this treatment regimen.

1.2.3 To evaluate the plasma pharmacokinetics of erlotinib in pancreatic cancer patients both in the preoperative and postoperative setting, and to explore correlations between plasma and tumor erlotinib concentrations.

1.2.4 To develop a clinically relevant predictive assay of response to erlotinib based on selected biomarkers in endoscopic ultrasound-fine needle aspiration (EUS-FNA) specimens when it can be obtained at the time of pancreatic cancer diagnosis in chemotherapy-naive patients.

Detailed Description

Our current clinical trial proposal includes a short course of pre-operative, single agent erlotinib followed by post-operative erlotinib-gemcitabine in a neo-adjuvant/adjuvant approach to the treatment of patients with resectable pancreatic adenocarcinoma. The short course pre-operative erlotinib treatment serves two objectives: 1) erlotinib, through its cytostatic effects, may hinder the ability of tumor cells to metastasize at the time of surgical resection with minimal toxic effects and no delay in surgical treatment; 2) the true effects of erlotinib on potential determinants of response can be best assayed on the pancreatic cancer itself since no other model can better resemble the patients authentic tumor microenvironment. The post-operative treatment component of the protocol attempts to improve the demonstrated effects of gemcitabine by adding erlotinib in the adjuvant setting, a drug combination that, as mentioned, has already been proven to be advantageous for patients with advanced pancreatic cancer.

Traditionally, chemotherapy for cancer has been conducted in an empiric fashion by first selecting a regimen based on clinical trial evidence and clinical parameters, and then by assessing the objective response to that regimen employing clinical and radiographic imaging means. This approach suffers from many disadvantages, most conspicuously the inability to select the better patient candidates prior to the initiation of therapy, thus sparing the risk and expense of ineffective treatment for patients who are unlikely to respond. Since pancreatic cancer expression of EGFR protein by itself is not predictive of therapeutic response, alternative methods of patient selection seem to be essential for the success of EGFR-targeted treatment. The understanding of EGFR molecular signaling has allowed the drug development process to shift from an empiric random screening approach to a more rational and mechanistic, target-directed approach. Among multiple attempts to identify molecular determinants of tumor cell sensitivity to EGFR inhibitors, there are two main paradigms that stand out: 1) activation of downstream pharmacodynamic effectors associated with response to the drug (i.e. phosphorylation of Akt or extracellular signal-regulated kinase (ERK); expression of c-fos), and 2) prediction of sensitivity based on a "static" analyte (detection of epidermal growth factor receptor (EGFR) sensitizing mutations; epithelial-mesenchymal transition profile). However, given the complexity of factors governing pancreatic cancer response to erlotinib, the biologic heterogeneity of malignant phenotype, and overall relatively low response rates, we believe that it is unlikely that analysis of a single biomarker will be useful for patient selection. A comprehensive analysis of a dynamic panel of biomarkers relevant to EGFR signaling and erlotinib mechanism of action seems more useful in that sense. Furthermore, the limited ability of pancreatic cancer tissue sampling often precludes biomarker correlation to assays worked out in xenograft models or in-vitro conditions.

The translational rationale of this proposal is therefore to develop predictive chemotherapy sensitivity-resistance assays (CSRA) for pancreas carcinoma patients treated with erlotinib and gemcitabine. This will represent a major advance, because the CSRA would enable prediction of clinical response prior to initiation of therapy.

Conditions

Pancreatic Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Eroltinib added to standard of care

150 mg of erlotinib for 7 days prior to surgery,then in the adjuvant stage the subject will receive 100mg of erlotinib and gemcitabine 1000mg/2 for 6 cycles

Group Type: EXPERIMENTAL

erlotinib

Intervention Type: DRUG

Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.

Interventions

erlotinib

Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.

Intervention Type: DRUG

Other Intervention Names

Tarceva

Eligibility Criteria

Inclusion Criteria

.Histologic or cytologic confirmation of pancreatic ductal adenocarcinoma.

• Pancreatic cancer must be surgically resectable: a) no evidence of distant metastasis; b) clear fat plane around the celiac and superior mesenteric arteries; c) patent portal and superior mesenteric veins
• No evidence of post-resection distant metastasis
• Pathologic confirmation of R0/R1 status following surgical resection
• Age ≥ 19 years
• Male or female gender (not pregnant or lactating). If the subject is fertile, use of medically acceptable contraception will be required.
• Patient should be able to understand and offer signed written informed consent prior to study entry.
• No prior receipt of chemotherapy or radiotherapy
• Patients must demonstrate a Eastern Cooperative Oncology Group(ECOG) P.S. of 0 or 1
• End Organ function must be adequate meeting the below criteria at baseline:

White Blood Cell Count (WBC)> 3000/mm3, absolute neutrophil count(ANC)> 1500/mm3, Platelets>100,000mm3 Calculated creatinine clearance >50 ml/min, normal serum creatinine (mg/dL) (if calculated Crcl <50 ml/min, Crcl should measured and be > 50 ml/min) Bilirubin <3.0 mg/dL (patients with obstructive jaundice require preoperative endoscopic biliary stenting if total bilirubin >3.0 mg/dl) prothrombin time(PT) /partial thromboplastin time(PTT) below the upper limit of normal

Exclusion Criteria

• Diagnosis of active (treated in past 5 years) concomitant malignancy with exception of non-melanotic skin cancer
• Transplant patients or patients receiving immunosuppression
• Presence of an underlying disease state associated with active bleeding or a past medical history of coagulopathy
• New York Heart Association Class IV congestive heart failure
• Limited mental capacity or language skills to the extent simple instructions cannot be followed or information regarding adverse events cannot be provided
• History of non-compliance with prescribed medical care

Post-Operative Phase Inclusion

• No Evidence of Post-Resection Distant Metastasis
• Pathological confirmation of R0/R1 status following Surgical resection
• Patient must demonstrate a post-operative performance status of 0 or 1.
• End Organ function must be adequate, meeting the below criteria at baseline:

1. WBC > 3000/mm³,ANC > 1500/mm³, Platelets > 100,000 mm³

2. Calculated Creatinine Clearance > 50 ml/min,Serum Creatinine < 1.5 mg/dl

3. Bilirubin < 3.0 mg/dl; aspartate aminotransferase(AST) and alanine aminotransferase (ALT) < 3 x normal value

4. PT/PTT/international normalized ratio(INR) within normal Limits.

-

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

OSI Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

University of Alabama at Birmingham

OTHER

Sponsor Role: lead

Responsible Party

Marty Heslin

Chief of section of Surgical Oncology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Juan P Arnoletti, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Alabama at Birmingham

Locations

University of Alabama at Birmingham,Comprehensive Cancer Center

Birmingham, Alabama, United States

Countries

United States

Other Identifiers

F080718006

Identifier Type: -

Identifier Source: org_study_id